Objective： To compare the pharmacokinetics and bioavailability of nicardipine hydrochloride sustained-release pellets (NIC-SP) with common market tablets and imported sustained-release capsules (Perdipine LA). Methods: Latin test was employed in the single oral administration of NIC-SP, common market tablets and Perdipine LA with 6 volunteers. The relative bioavailabilities of NIC-SP against market tablet and Perdipine LA were calculated. Results: The bioavailability of NIC-SP against Perdipine LA is 116.09%. The bioavailabilities of NIC-SP and Perdipine LA against market tablet is 86.53%and 74.54%, respectively. There were significant differences between AUC, MRT of NIC-SP and Perdipine LA (P<0.05), while tmax,cmax,ke and ka of them did not show significant difference(P>0.05). Conclusion: The sustained effect of NIC-SP is better than the Perdipine LA in vivo.